|
Research Management and Support
|
RMS ES 2016
|
$320,501,735
|
$101,000
|
N/A
|
National Institutes of Health
|
|
COG NCTN Network Group Operations Center
|
3U10CA180886-03S1
|
$3,025,319
|
$242,026
|
ADAMSON, PETER
|
CHILDREN'S HOSP OF PHILADELPHIA
|
|
COG NCTN Solid Malignancy Integrated Translational Science Center
|
5U10CA180884-03
|
$400,000
|
$80,000
|
ADAMSON, PETER
|
CHILDREN'S HOSP OF PHILADELPHIA
|
|
COG NCTN Network Group Operations Center
|
5U10CA180886-03
|
$21,084,883
|
$1,686,791
|
ADAMSON, PETER
|
CHILDREN'S HOSP OF PHILADELPHIA
|
|
Childhood Cancer Survivor Study
|
4U24CA055727-22
|
$4,172,004
|
$417,200
|
ARMSTRONG, GREGORY
|
ST. JUDE CHILDREN'S RESEARCH HOSPITAL
|
|
Molecular Diagnostics for Risk Stratification and Monitoring of Neuroblastoma
|
5R01CA182633-03
|
$665,155
|
$665,155
|
ASGHARZADEH, SHAHAB
|
CHILDREN'S HOSPITAL OF LOS ANGELES
|
|
Cancer Center Support Grant
|
3P30CA082103-18S1
|
$121,856
|
$2,437
|
ASHWORTH, ALAN
|
UNIVERSITY OF CALIFORNIA, SAN FRANCISCO
|
|
Cancer Center Support Grant
|
3P30CA082103-18S2
|
$155,534
|
$3,111
|
ASHWORTH, ALAN
|
UNIVERSITY OF CALIFORNIA, SAN FRANCISCO
|
|
Cancer Center Support Grant
|
3P30CA082103-18S3
|
$60,000
|
$1,200
|
ASHWORTH, ALAN
|
UNIVERSITY OF CALIFORNIA, SAN FRANCISCO
|
|
Cancer Center Support Grant
|
3P30CA082103-18S4
|
$80,100
|
$1,602
|
ASHWORTH, ALAN
|
UNIVERSITY OF CALIFORNIA, SAN FRANCISCO
|
|
Cancer Center Support Grant
|
3P30CA082103-18S5
|
$200,000
|
$4,000
|
ASHWORTH, ALAN
|
UNIVERSITY OF CALIFORNIA, SAN FRANCISCO
|
|
Cancer Center Support Grant
|
3P30CA082103-18S6
|
$152,100
|
$3,042
|
ASHWORTH, ALAN
|
UNIVERSITY OF CALIFORNIA, SAN FRANCISCO
|
|
Cancer Center Support Grant
|
3P30CA082103-18S7
|
$200,000
|
$4,000
|
ASHWORTH, ALAN
|
UNIVERSITY OF CALIFORNIA, SAN FRANCISCO
|
|
Cancer Center Support Grant
|
3P30CA082103-18S8
|
$749,207
|
$14,984
|
ASHWORTH, ALAN
|
UNIVERSITY OF CALIFORNIA, SAN FRANCISCO
|
|
Cancer Center Support Grant
|
4P30CA082103-18
|
$7,063,742
|
$141,275
|
ASHWORTH, ALAN
|
UNIVERSITY OF CALIFORNIA, SAN FRANCISCO
|
|
Second generation MIBG analogs that cotarget DNA for high risk neuroblastoma
|
1R21CA187548-01A1
|
$196,403
|
$196,403
|
BARANOWSKA-KORTYLEWICZ, JANINA
|
UNIVERSITY OF NEBRASKA MEDICAL CENTER
|
|
Systems Biology of Tumor Progression and Drug Resistance
|
4U01CA168426-05
|
$1,238,106
|
$1,238,106
|
CALIFANO, ANDREA
|
COLUMBIA UNIVERSITY HEALTH SCIENCES
|
|
Fred & Pamela Buffett Cancer Center Support Grant
|
2P30CA036727-30
|
$2,107,000
|
$42,140
|
COWAN, KENNETH
|
UNIVERSITY OF NEBRASKA MEDICAL CENTER
|
|
Fred & Pamela Buffett Cancer Center Support Grant
|
3P30CA036727-30S1
|
$50,000
|
$1,000
|
COWAN, KENNETH
|
UNIVERSITY OF NEBRASKA MEDICAL CENTER
|
|
Fred & Pamela Buffett Cancer Center Support Grant
|
3P30CA036727-30S2
|
$64,625
|
$1,293
|
COWAN, KENNETH
|
UNIVERSITY OF NEBRASKA MEDICAL CENTER
|
|
Abramson Cancer Center Support Grant
|
2P30CA016520-40
|
$7,975,543
|
$558,288
|
DANG, CHI
|
UNIVERSITY OF PENNSYLVANIA
|
|
Abramson Cancer Center Support Grant
|
3P30CA016520-40S1
|
$31,250
|
$2,188
|
DANG, CHI
|
UNIVERSITY OF PENNSYLVANIA
|
|
Abramson Cancer Center Support Grant
|
3P30CA016520-40S2
|
$499,967
|
$34,998
|
DANG, CHI
|
UNIVERSITY OF PENNSYLVANIA
|
|
Abramson Cancer Center Support Grant
|
3P30CA016520-40S3
|
$200,000
|
$14,000
|
DANG, CHI
|
UNIVERSITY OF PENNSYLVANIA
|
|
MYC--Transcription and Apoptosis
|
5R01CA051497-25
|
$733,273
|
$366,637
|
DANG, CHI
|
UNIVERSITY OF PENNSYLVANIA
|
|
Training Physician Scientists in Pediatric Oncology
|
2T32CA009659-21A1
|
$64,768
|
$32,384
|
DECLERCK, YVES
|
CHILDREN'S HOSPITAL OF LOS ANGELES
|
|
Plasminogen activator inhibitor-1 in tumor progression and metastasis
|
4R01CA129377-09
|
$239,246
|
$239,246
|
DECLERCK, YVES
|
CHILDREN'S HOSPITAL OF LOS ANGELES
|
|
Structural Variation in Neuroblastoma
|
1R01CA204974-01A1
|
$384,300
|
$384,300
|
DISKIN, SHARON
|
CHILDREN'S HOSP OF PHILADELPHIA
|
|
Optimizing 131I-mIBG Therapy for Children with Advanced Neuroblastoma
|
5R01CA172067-05
|
$363,426
|
$363,426
|
DUBOIS, STEVEN
|
DANA-FARBER CANCER INST
|
|
Maximizing cancer synthetic lethality using dual PI-3K/PARP inhibitors
|
1R41CA206859-01A1
|
$299,738
|
$149,869
|
DURDEN, DONALD
|
SIGNALRX PHARMACEUTICALS, INC.
|
|
Employing the Myc Transcriptional Network to Reveal Oncogenic Pathways
|
5R01CA057138-25
|
$635,460
|
$317,730
|
EISENMAN, ROBERT
|
FRED HUTCHINSON CANCER RESEARCH CENTER
|
|
Cancer Center Support Grant
|
3P30CA013696-42S1
|
$120,000
|
$4,800
|
EMERSON, STEPHEN
|
COLUMBIA UNIVERSITY HEALTH SCIENCES
|
|
Cancer Center Support Grant
|
3P30CA013696-42S2
|
$60,000
|
$2,400
|
EMERSON, STEPHEN
|
COLUMBIA UNIVERSITY HEALTH SCIENCES
|
|
Cancer Center Support Grant
|
3P30CA013696-42S3
|
$121,873
|
$4,875
|
EMERSON, STEPHEN
|
COLUMBIA UNIVERSITY HEALTH SCIENCES
|
|
Cancer Center Support Grant
|
3P30CA013696-42S4
|
$150,866
|
$6,035
|
EMERSON, STEPHEN
|
COLUMBIA UNIVERSITY HEALTH SCIENCES
|
|
Cancer Center Support Grant
|
3P30CA013696-42S5
|
$199,541
|
$7,982
|
EMERSON, STEPHEN
|
COLUMBIA UNIVERSITY HEALTH SCIENCES
|
|
Cancer Center Support Grant
|
3P30CA013696-42S6
|
$500,000
|
$20,000
|
EMERSON, STEPHEN
|
COLUMBIA UNIVERSITY HEALTH SCIENCES
|
|
Cancer Center Support Grant
|
5P30CA013696-42
|
$3,792,720
|
$151,709
|
EMERSON, STEPHEN
|
COLUMBIA UNIVERSITY HEALTH SCIENCES
|
|
Sphingosine-1-Phosphate Pathway Based Therapy for Neuroblastoma
|
4R01CA168903-05
|
$345,402
|
$345,402
|
FERRER, FERNANDO
|
UNIVERSITY OF CONNECTICUT SCH OF MED/DNT
|
|
Molecular determinants of PARP inhibitor sensitivity in 11q-deleted malignancy
|
5R21CA181417-02
|
$219,957
|
$109,979
|
FRANCO, SONIA
|
JOHNS HOPKINS UNIVERSITY
|
|
Epigenetic Regulation of Neuroblast Differentiation
|
5F31CA192558-02
|
$34,000
|
$34,000
|
GAVIGLIO, ANGELA
|
DUKE UNIVERSITY
|
|
Transcriptional CDKs as therapeutic targets in MYC-dependent cancers
|
1R01CA197336-01A1
|
$407,748
|
$407,748
|
GEORGE, RANI
|
DANA-FARBER CANCER INST
|
|
Pediatric Oncology Branch Clinical Care and Education
|
ZIE BC 011516
|
$3,340,699
|
$167,035
|
Glod, John
|
CCR (NCI)
|
|
USC Norris Comprehensive Cancer Center (Core) Grant
|
2P30CA014089-41
|
$6,354,897
|
$381,294
|
GRUBER, STEPHEN
|
UNIVERSITY OF SOUTHERN CALIFORNIA
|
|
USC Norris Comprehensive Cancer Center (Core) Grant
|
3P30CA014089-41S1
|
$59,999
|
$3,600
|
GRUBER, STEPHEN
|
UNIVERSITY OF SOUTHERN CALIFORNIA
|
|
USC Norris Comprehensive Cancer Center (Core) Grant
|
3P30CA014089-41S2
|
$37,500
|
$2,250
|
GRUBER, STEPHEN
|
UNIVERSITY OF SOUTHERN CALIFORNIA
|
|
HAUSP inhibitors in p53-wild type and p53-mutant tumors
|
5R01CA193890-02
|
$366,000
|
$91,500
|
GU, WEI
|
COLUMBIA UNIVERSITY HEALTH SCIENCES
|
|
Deciphering the Molecular Pathways Driving p53 Dependent Cell Death
|
5F32CA199716-03
|
$58,002
|
$29,001
|
GUARNIERI, ANNA
|
UNIVERSITY OF COLORADO DENVER
|
|
Enhancing T Cell Therapy of Cancer
|
4P01CA094237-14
|
$1,932,287
|
$483,072
|
HESLOP, HELEN
|
BAYLOR COLLEGE OF MEDICINE
|
|
Development of new antibody-based cancer therapies
|
ZIA BC 010891
|
$817,629
|
$817,629
|
Ho, Mitchell
|
CCR (NCI)
|
Total relevant funding to Neuroblastoma for this search: $19,959,764
|